Gene therapy focuses on genetic modification to produce therapeutic effects or treat
diseases by repairing or reconstructing genetic material, thus being expected to be the most …

Sensorineural hearing loss (SNHL) is the most common sensory disorder. Its underlying
etiologies include a broad spectrum of genetic and environmental factors that can lead to …

The use of viral vectors for inner ear gene therapy is receiving increased attention for
treatment of genetic hearing disorders. Most animal studies to date have injected viral …

Dizziness and hearing loss are among the most common disabilities. Many forms of
hereditary balance and hearing disorders are caused by abnormal development of …

Impairments of vision and hearing are highly prevalent conditions limiting the quality of life
and presenting a major socioeconomic burden. For a long time, retinal and cochlear …

Cochlear gene therapy holds promise for the treatment of genetic deafness. Assessing its
impact in adult murine models of hearing loss, however, has been hampered by technical …

An estimated 466 million people suffer from hearing loss worldwide. Sensorineural hearing
loss is characterized by degeneration of key structures of the sensory pathway in the …

Mutations in GJB2, which codes for the gap junction (GJ) protein connexin26 (Cx26), are the
most common causes of human nonsyndromic hereditary deafness. We inoculated modified …

Mutations in the potassium channel subunit KCNQ 1 cause the human severe congenital
deafness Jervell and Lange‐Nielsen (JLN) syndrome. We applied a gene therapy approach …

Hearing loss, including genetic hearing loss, is one of the most common forms of sensory
deficits in humans with limited options of treatment. Adeno-associated virus (AAV)-mediated …